What is the survival rate for glioblastoma multiforme?
Glioblastoma
Despite maximum treatment, the cancer usually recurs.[3] The most common length of survival following diagnosis is 12 to 15 months, with fewer than 3% to 5% of people surviving longer than five years.[2][3] Without treatment, survival is typically three months.[9] It is the most common cancer that begins within the brain and the second most common brain tumor, after meningioma.[5][10] About 3 per 100,000 people develop the disease a year.[3] It most often begins around 64 years of age and occurs more commonly in males than females.[2][3] Immunotherapy is being studied.[11]
MIAT (gene)
In a study of glioblastoma multiforme, increased expression of MIAT was linked to increased survival rates. In addition, the glioma cells were found to how significantly down-regulated MIAT. The role of MIAT in lymphocytic leukemia is very different from that of glioblastoma. In certain aggressive cell lines of chronic lymphocytic leukemias, MIAT is upregulated and depends on the presence of a transcriptional regulator, OCT4. OCT4 serves a positive regulator of MIAT transcription and as of now is the only known regulator. However, analysis of relative concentrations of MIAT and OCT4 have indicated that other regulatory factors are in play.